NO126201B - - Google Patents
Download PDFInfo
- Publication number
- NO126201B NO126201B NO16510066A NO16510066A NO126201B NO 126201 B NO126201 B NO 126201B NO 16510066 A NO16510066 A NO 16510066A NO 16510066 A NO16510066 A NO 16510066A NO 126201 B NO126201 B NO 126201B
- Authority
- NO
- Norway
- Prior art keywords
- tablets
- tablet
- release
- active substance
- substance
- Prior art date
Links
- 239000000126 substance Substances 0.000 claims description 28
- 239000013543 active substance Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 for example. beeswax Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BSFJGCCAXDCMOX-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(4-methylpyrimidin-2-yl)azanide Chemical class [Na+].CC1=CC=NC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 BSFJGCCAXDCMOX-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/003—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic followed by coating of the granules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/006—Coating of the granules without description of the process or the device by which the granules are obtained
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK522265 | 1965-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO126201B true NO126201B (da) | 1973-01-08 |
Family
ID=8140572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO16510066A NO126201B (da) | 1965-10-12 | 1966-10-11 |
Country Status (11)
| Country | Link |
|---|---|
| BE (1) | BE688121A (da) |
| BR (1) | BR6683606D0 (da) |
| CA (1) | CA983393A (da) |
| DE (1) | DE1617593A1 (da) |
| ES (1) | ES332215A1 (da) |
| FI (1) | FI48245B (da) |
| FR (1) | FR1602625A (da) |
| GB (1) | GB1137156A (da) |
| NL (1) | NL6614357A (da) |
| NO (1) | NO126201B (da) |
| SE (1) | SE337281C (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI53921C (fi) * | 1971-06-04 | 1978-09-11 | Boehringer Mannheim Gmbh | Foerfarande foer granulering av tablettmassor i pulverform |
| FR2231365B1 (da) * | 1973-05-29 | 1977-11-04 | Hoffmann La Roche | |
| FR2383659A1 (fr) * | 1977-03-16 | 1978-10-13 | Berri Balzac | Procede de preparation de comprimes contenant des substances labiles en microdispersion |
| US4673527A (en) * | 1985-05-20 | 1987-06-16 | Autotrol Corporation | Tablet granulation |
| JPH03232814A (ja) * | 1990-02-08 | 1991-10-16 | Shin Etsu Chem Co Ltd | 徐放性錠剤の製造方法 |
| EP0620728B1 (en) * | 1992-01-13 | 1997-01-08 | Pfizer Inc. | Preparation of tablets of increased strength |
| DE19729487A1 (de) * | 1997-07-10 | 1999-01-14 | Dresden Arzneimittel | Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix |
| CN103948556A (zh) * | 2014-04-08 | 2014-07-30 | 闻晓光 | 一种新型控释片 |
-
1966
- 1966-09-24 DE DE19661617593 patent/DE1617593A1/de active Pending
- 1966-10-06 GB GB4463266A patent/GB1137156A/en not_active Expired
- 1966-10-07 FI FI264266A patent/FI48245B/fi active
- 1966-10-11 FR FR1602625D patent/FR1602625A/fr not_active Expired
- 1966-10-11 SE SE6613760A patent/SE337281C/xx unknown
- 1966-10-11 NO NO16510066A patent/NO126201B/no unknown
- 1966-10-12 NL NL6614357A patent/NL6614357A/xx unknown
- 1966-10-12 BE BE688121A patent/BE688121A/xx unknown
- 1966-10-12 CA CA972,775A patent/CA983393A/en not_active Expired
- 1966-10-12 BR BR18360666A patent/BR6683606D0/pt unknown
- 1966-10-13 ES ES332215A patent/ES332215A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL6614357A (da) | 1967-04-13 |
| SE337281C (da) | 1975-10-20 |
| BE688121A (da) | 1967-04-12 |
| SE337281B (da) | 1971-08-02 |
| ES332215A1 (es) | 1968-05-01 |
| FI48245B (da) | 1974-04-30 |
| FR1602625A (en) | 1971-01-04 |
| CA983393A (en) | 1976-02-10 |
| DE1617593A1 (de) | 1971-04-29 |
| BR6683606D0 (pt) | 1973-11-13 |
| GB1137156A (en) | 1968-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3107566B2 (ja) | 固態溶解による製薬的及び他のマトリクス系の生成 | |
| US3279998A (en) | Method of preparing sustained release tablets | |
| CA1247009A (en) | Diffusion coated multiple-units dosage form | |
| US4140756A (en) | Film-coated matrix core tablet | |
| DK170244B1 (da) | Indretning til kontrolleret afgivelse af aktive substanser samt fremgangsmåde til fremstilling af en sådan indretning | |
| AU653048B2 (en) | Controlled release matrix for pharmaceuticals | |
| US5648093A (en) | Pharmaceutical and other dosage forms | |
| US5055306A (en) | Sustained-release formulations | |
| US5855915A (en) | Tablets or biologically acceptable implants for long-term antiinflammatory drug release | |
| US4900755A (en) | Controlled release combination of carbidopa/levodopa | |
| NO175240B (no) | Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler | |
| JPH05221854A (ja) | 水溶性薬物を含有する制御的放出錠剤 | |
| US4983400A (en) | Controlled release combination of carbidopa/levodopa | |
| WO2014154029A1 (zh) | 复合骨架材料及其药物组合物 | |
| JP2000508649A (ja) | 速崩解性経口剤形物 | |
| JP2000514406A (ja) | アルギン酸から成る経口投与製剤用腸溶性被膜 | |
| JPH03184911A (ja) | 錠剤にした経口的投与単位形態の球状顆粒からの制御された解放の製剤学的組成物 | |
| NO318890B1 (no) | Oksykodonformuleringer med kontrollert frigivelse og anvendelse av slike for fremstilling av smertelindrende medikamenter | |
| IE883679L (en) | Controlled release combination of carbidopa/levodopa | |
| CN101987083B (zh) | 一种控释制剂特别是零级释放的控释制剂制备方法 | |
| JPH07116028B2 (ja) | 持続性ジクロフエナクナトリウム製剤 | |
| CN104013592A (zh) | 盐酸美金刚缓释药丸及其制备方法 | |
| NO126201B (da) | ||
| JPH0625064B2 (ja) | 制御放出塩化カリウム | |
| US20210228492A1 (en) | Multiparticulate including pharmaceutical or probiotic active ingredients for delivery via a shelf stable liquid dosage form |